Akshanth R. Polepally, Ph.D.
Affiliations: | 2012 | Experimental & Clinical Pharmacology | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Pharmacology, PharmacyGoogle:
"Akshanth Polepally"Mean distance: 23748
Parents
Sign in to add mentor| Angela K. Birnbaum | grad student | 2012 | UMN | |
| (Pharmacometric analyses of lamotrigine in special populations: Application to pregnant women, younger adult and elderly epilepsy patients.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Polepally AR, Ng JW, Salem AH, et al. (2020) Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology |
| Shebley M, Polepally AR, Nader A, et al. (2019) Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics |
| Khatri A, Suleiman AA, Polepally AR, et al. (2019) Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase 2 and 3 Trials in Psoriasis Patients. Clinical Pharmacology and Therapeutics |
| Poordad F, Sedghi S, Pockros PJ, et al. (2019) Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. Journal of Viral Hepatitis |
| Polepally AR, Brundage RC, Remmel RP, et al. (2018) Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. Epilepsia |
| Winzenborg I, Nader A, Polepally AR, et al. (2018) Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics |
| Polepally AR, Wang H, Marroum PJ, et al. (2017) Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The Aaps Journal |
| Menon RM, Polepally AR, Khatri A, et al. (2017) Clinical Pharmacokinetics of Paritaprevir. Clinical Pharmacokinetics |
| Mensing S, Eckert D, Sharma S, et al. (2016) Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in hepatitis C virus genotype 1 infection: analysis of 6 phase 3 trials. British Journal of Clinical Pharmacology |
| Polepally AR, Badri PS, Parikh A, et al. (2016) Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. Antiviral Therapy |